FFO
OBIO icon

Fortitude Family Office’s Orchestra BioMed OBIO Stock Holding History

Fortitude Family Office’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-203
Closed -$544 – 2096
2025
Q2 		$544 Buy
+203
New +$593 ﹤0.01% 1760

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fortitude Family Office's OBIO Position: Q3 2025 in Review

Fortitude Family Office sold out of Orchestra BioMed (OBIO) in Q3 2025, closing a stake of 203 shares — an estimated $544 sold.

Fortitude Family Office first reported a position in OBIO in Q2 2025 and held it in 1 quarter. The position peaked at $544 in Q2 2025. 52 funds tracked by Wall St. Rank hold OBIO as of Q3 2025.

  • Fortitude Family Office reported no remaining Orchestra BioMed position as of Q3 2025 after selling out during the quarter.
  • Fortitude Family Office sold 203 Orchestra BioMed shares in Q3 2025, an estimated $544.
  • Fortitude Family Office first reported a position in Orchestra BioMed in Q2 2025 and held it in 1 quarter.
  • Fortitude Family Office's Orchestra BioMed position peaked at $544 in Q2 2025.
  • 52 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2025.

Based on Fortitude Family Office's 13F filing for Q3 2025, filed 17 Oct 2025.